Wuhan Createrna Science and Technology Co. Ltd. has synthesized new cyclobutenedione compounds acting as C-C chemokine receptor type 6 (CCR6) antagonists potentially useful for the treatment of inflammatory bowel disease, allergy, dry eye, psoriasis, rheumatoid arthritis and multiple sclerosis.